The Intersection of Health Economics, AI and Health Outcomes

By Sumona Bose

February 1, 2024

Introduction

In recent years, the healthcare industry has witnessed a surge in the use of artificial intelligence (AI) technologies to improve patient care and outcomes. As the field of health economics and outcomes research (HEOR) continues to evolve, it is crucial to understand the economic evaluations of AI-based health interventions. A recent study conducted by Voets et al. provides valuable insights into the current landscape of AI in healthcare. This article aims to summarize the key findings of the study and shed light on the merged perspectives of HEOR, AI, and health outcomes. The application of Health Economics in AI allows us to analyse a balanced view of how intrinsic digital innovation is in the healthcare landscape. This article authored by Vithlani et al., builds on the progressive work of Voets et al.

Relevance of Economic Evaluations

Economic evaluations play a crucial role in assessing the value of AI-based health interventions. The original review by Voets et al. found that cost minimization was the prevailing type of health economic evaluation (HEE). However, the updated review reveals a shift towards cost-utility analysis (CUA) as the most common study type. This change suggests a growing emphasis on assessing the broader economic and health outcomes of AI interventions. The application of Health Economics into AI brings about numerous debates on how evaluative methodologies are efficient.

Model-Based Evaluations

The updated review also highlights a significant difference in the use of model-based evaluations compared to the original review. The study found that 45% of the HEEs were model-based, the updated review indicates that the large majority of HEEs now employ this approach. Model-based evaluations allow for estimating future costs and benefits of AI technologies.

www.frontiersin.org
Figure 1: Summary of economic evaluation parameters and outcomes.

Limitations and Reporting Standards

Despite the increase in the use of sophisticated economic evaluation techniques, the evidence supporting these methods remains limited. The quality assessment conducted in the study revealed potentially serious limitations in the sources and assumptions regarding input data. The reporting of HEEs also lacked clarity, making it challenging to determine fundamental aspects such as cost application, integration with clinical care, and anticipated users of AI interventions.

Conclusion

The intersection of health economics, AI, and health outcomes is a rapidly evolving field with significant implications for the healthcare industry. The study conducted by Voets et al. provides valuable insights into the current landscape of AI in healthcare. It highlights the need for economic evaluations of AI-based health interventions. It found that AI health technologies are on the rise, with automated image analysis being the most commonly evaluated purpose of AI interventions. The shift towards cost-utility analysis suggests a growing emphasis on assessing the broader economic and health outcomes of AI interventions.

Reference url

Recent Posts

biosimilars price competition
      

The Impact of MFN Pricing on the U.S. Biosimilar Market

💊 Could MFN Pricing Undermine Biosimilars?

MFN drug pricing aims to cut costs—but its indirect pressure on biosimilars may reduce competition (create a void) and raise long-term prices.

Explore the risks and what stakeholders can do to protect market sustainability.

#SyenzaNews #Biosimilars #DrugPricing #HealthPolicy #Pharma #MarketAccess

EU AI Act Healthcare Compliance
     

Navigating EU AI Act Healthcare Compliance: Proactive Steps for Ethical AI Integration

🔍 Are you prepared for the upcoming EU AI Act in healthcare?

As the first comprehensive AI regulation globally rolls out, healthcare organizations must move beyond mere compliance. The urgency lies in embedding ethical, trusted, and sustainable AI practices into every facet of healthcare AI. Early adoption of ethical assessments and collaboration is essential to navigate the complex regulatory landscape before the August 2026 deadline.

Learn about proactive compliance strategies that not only meet regulatory standards but also enhance patient trust and system efficacy!

#SyenzaNews #AIinHealthcare #HealthcareInnovation #DigitalTransformation

hepatitis vaccine uptake
         

Hepatitis Vaccine Uptake: Trends, Challenges, and the Role of Pharmacists

💉 Are we doing enough to bridge the gap in hepatitis vaccine uptake?

A recent article highlights that while over 90% of children are vaccinated against hepatitis B, adult rates are alarmingly low, posing a significant public health risk. Jeff Goad from the National Foundation for Infectious Diseases emphasizes the crucial role pharmacists can play in increasing access and dispelling common misconceptions about vaccines.

Join the conversation on enhancing vaccination strategies for better health outcomes!

#SyenzaNews #Healthcare #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.